176 related articles for article (PubMed ID: 14605997)
21. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.
Nauck MA; Sauerwald A; Ritzel R; Holst JJ; Schmiegel W
Diabetes Care; 1998 Nov; 21(11):1925-31. PubMed ID: 9802745
[TBL] [Abstract][Full Text] [Related]
22. Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus.
Zenobi PD; Jaeggi-Groisman SE; Riesen WF; Røder ME; Froesch ER
J Clin Invest; 1992 Dec; 90(6):2234-41. PubMed ID: 1469083
[TBL] [Abstract][Full Text] [Related]
23. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.
Creutzfeldt WO; Kleine N; Willms B; Orskov C; Holst JJ; Nauck MA
Diabetes Care; 1996 Jun; 19(6):580-6. PubMed ID: 8725855
[TBL] [Abstract][Full Text] [Related]
24. A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy.
Gitt AK; Bramlage P; Schneider S; Tschöpe D
Cardiovasc Diabetol; 2015 Feb; 14():13. PubMed ID: 25645672
[TBL] [Abstract][Full Text] [Related]
25. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.
Nauck MA; Weber I; Bach I; Richter S; Orskov C; Holst JJ; Schmiegel W
Diabet Med; 1998 Nov; 15(11):937-45. PubMed ID: 9827848
[TBL] [Abstract][Full Text] [Related]
26. GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions.
Gutniak MK; Larsson H; Sanders SW; Juneskans O; Holst JJ; Ahrén B
Diabetes Care; 1997 Dec; 20(12):1874-9. PubMed ID: 9405910
[TBL] [Abstract][Full Text] [Related]
27. Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes.
Zander M; Taskiran M; Toft-Nielsen MB; Madsbad S; Holst JJ
Diabetes Care; 2001 Apr; 24(4):720-5. PubMed ID: 11315837
[TBL] [Abstract][Full Text] [Related]
28. Impact of the timing of metformin administration on glycaemic and glucagon-like peptide-1 responses to intraduodenal glucose infusion in type 2 diabetes: a double-blind, randomised, placebo-controlled, crossover study.
Xie C; Iroga P; Bound MJ; Grivell J; Huang W; Jones KL; Horowitz M; Rayner CK; Wu T
Diabetologia; 2024 Jul; 67(7):1260-1270. PubMed ID: 38561463
[TBL] [Abstract][Full Text] [Related]
29. Once-weekly dulaglutide 1.5 mg restores insulin secretion in response to intravenous glucose infusion.
de la Peña A; Loghin C; Cui X; Zhang X; Kapitza C; Kelly RP
Diabetes Obes Metab; 2017 Apr; 19(4):517-523. PubMed ID: 27976833
[TBL] [Abstract][Full Text] [Related]
30. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.
Nauck MA; Kleine N; Orskov C; Holst JJ; Willms B; Creutzfeldt W
Diabetologia; 1993 Aug; 36(8):741-4. PubMed ID: 8405741
[TBL] [Abstract][Full Text] [Related]
31. Intravenous GLP-1 (7-36) amide for prevention of hyperglycemia during cardiac surgery: a randomized, double-blind, placebo-controlled study.
Kohl BA; Hammond MS; Cucchiara AJ; Ochroch EA
J Cardiothorac Vasc Anesth; 2014 Jun; 28(3):618-25. PubMed ID: 24144627
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships.
Ritzel R; Orskov C; Holst JJ; Nauck MA
Diabetologia; 1995 Jun; 38(6):720-5. PubMed ID: 7672496
[TBL] [Abstract][Full Text] [Related]
33. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects.
Barrington P; Chien JY; Tibaldi F; Showalter HD; Schneck K; Ellis B
Diabetes Obes Metab; 2011 May; 13(5):434-8. PubMed ID: 21251179
[TBL] [Abstract][Full Text] [Related]
34. Hydrolyzed casein decreases postprandial glucose concentrations in T2DM patients irrespective of leucine content.
Geerts BF; van Dongen MG; Flameling B; Moerland MM; de Kam ML; Cohen AF; Romijn JA; Gerhardt CC; Kloek J; Burggraaf J
J Diet Suppl; 2011 Sep; 8(3):280-92. PubMed ID: 22432727
[TBL] [Abstract][Full Text] [Related]
35. Effects of multiple ascending doses of the glucagon receptor antagonist PF-06291874 in patients with type 2 diabetes mellitus.
Kazierad DJ; Bergman A; Tan B; Erion DM; Somayaji V; Lee DS; Rolph T
Diabetes Obes Metab; 2016 Aug; 18(8):795-802. PubMed ID: 27059951
[TBL] [Abstract][Full Text] [Related]
36. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.
Kolterman OG; Buse JB; Fineman MS; Gaines E; Heintz S; Bicsak TA; Taylor K; Kim D; Aisporna M; Wang Y; Baron AD
J Clin Endocrinol Metab; 2003 Jul; 88(7):3082-9. PubMed ID: 12843147
[TBL] [Abstract][Full Text] [Related]
37. Comparison of a carbohydrate-free diet vs. fasting on plasma glucose, insulin and glucagon in type 2 diabetes.
Nuttall FQ; Almokayyad RM; Gannon MC
Metabolism; 2015 Feb; 64(2):253-62. PubMed ID: 25458830
[TBL] [Abstract][Full Text] [Related]
38. Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus.
Schmitt C; Portron A; Jadidi S; Sarkar N; DiMarchi R
Diabetes Obes Metab; 2017 Oct; 19(10):1436-1445. PubMed ID: 28730694
[TBL] [Abstract][Full Text] [Related]
39. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.
Gutniak M; Orskov C; Holst JJ; Ahrén B; Efendic S
N Engl J Med; 1992 May; 326(20):1316-22. PubMed ID: 1348845
[TBL] [Abstract][Full Text] [Related]
40. Pharmacology of the glucagon-like peptide-1 analog exenatide extended-release in healthy cats.
Rudinsky AJ; Adin CA; Borin-Crivellenti S; Rajala-Schultz P; Hall MJ; Gilor C
Domest Anim Endocrinol; 2015 Apr; 51():78-85. PubMed ID: 25594949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
